Deoxycytidine kinase binding compounds for cancer and immune disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating diseases related to deoxycytidine kinase (dCK) activity are limited by the lack of effective probes for monitoring immune function and the development of resistance to antiviral and anticancer chemotherapeutic agents, as well as the need for compounds that can inhibit dCK activity in vivo.
Innovation Solution
Development of compounds that bind to and inhibit dCK activity, including a specific compound of formula (I) and its salts, which can be used in therapeutic methods for treating cancers and immune disorders, and as PET probes for imaging dCK activity in vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are developed to inhibit dCK activity in vivo, then therapeutic effectiveness against cancers and immune disorders is improved, but the complexity of drug development and clinical application increases
Solution Approach 1:
The patent segments the therapeutic approach by developing specific compound classes (e.g., compounds of formula I and formula II) with distinct structural features that target dCK activity. This segmentation allows for systematic optimization of therapeutic effectiveness while managing development complexity through modular chemical design.
Solution Approach 2:
The patent applies parameter changes by systematically varying chemical parameters (substituents R1-R17, ring structures, linker groups) in the compound formulas to optimize dCK inhibition. This enables fine-tuning of therapeutic effectiveness while providing a structured framework that manages development complexity through defined parameter spaces.
2Measurement precision
If PET probes are developed for imaging dCK activity, then diagnostic capability is improved, but the difficulty of detecting and measuring dCK activity in vivo increases
Solution Approach 1:
The patent uses PET probes as intermediary molecules that bind to dCK and serve as mediators for non-invasive imaging. These probes translate internal dCK activity into detectable external signals (positron emission), thereby improving diagnostic capability while overcoming the difficulty of direct in vivo measurement.
Solution Approach 2:
The patent replaces direct mechanical or biochemical measurement of dCK activity with optical/radiological detection methods. By substituting complex in vivo measurement mechanisms with PET imaging technology, the patent improves diagnostic capability while simplifying the detection process.
Data Source
AI summary
The invention provides compounds that bind to deoxycytidine kinase (dCK) and compositions including pharmaceutically acceptable compositions containing the compounds. The compounds are useful in treating diseases and disorders where dCK activity is implicated such as cancer and immune disorders. The compounds also find use in clinical methodologies including positron emission tomography (PET) imaging.